Navigation Links
Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
Date:2/3/2010

s of $24.3 million, or $0.60 per share, for the year ended December 31, 2008.  Revenues were $22.2 million for 2009, compared to $16.2 million in 2008. The increase in revenues for 2009 was primarily attributable to revenues from the Company's expanded agreement with Sigma-Aldrich. Total operating expenses were $41.6 million in both 2009 and 2008.

2009 Accomplishments and Recent Highlights

Therapeutic Programs and Research

  • Clinical Development Progress in Sangamo's Lead Therapeutic Program in DN and Renewed Program Support from JDRF: In January 2010, Sangamo initiated a Phase 2b trial of SB-509 in subjects with moderately severe DN.  The Juvenile Diabetes Research Foundation International (JDRF) also renewed its support for this program and will provide up to $3.0 million of funding for the trial. Sangamo's double blind, repeat-dosing, placebo controlled Phase 2b study, SB-509-901, is designed to finalize dose, schedule and primary and secondary approvable endpoints for pivotal Phase 3 trials.  Inclusion criteria for the trial are based upon accumulated data from Sangamo's earlier Phase 1 and Phase 2 clinical trials in subjects with DN that defined a drug-responsive population. The data included top-line, statistically significant data from the company's Phase 2 trial, SB-509-601, that established a mechanistic proof of concept for the neuroregenerative effects of SB-509 treatment as demonstrated by statistically significant increases in intraepidermal nerve fiber density (IENFD).  In addition, improvements in clinically relevant outcomes were observed in Neurologic Impairment Score of the Lower Limb
    '/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
2. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
3. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
4. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
5. Sangamo Announces Pricing of Public Offering of Common Stock
6. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
7. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
8. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
9. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
10. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Spartan Bioscience today announced that Paul ... by the Ottawa Chamber of Commerce as one of ... selected from over 240 applicants based on his business ... Spartan, Dr. Lem founded Plexagen Diagnostics, and also served ... a Medical Degree from the University of Ottawa, and ...
(Date:4/27/2015)... , April 27, 2015  For about a ... is their ability to utilize and catabolize glucose ... cancer cells is called the ,Warburg phenomenon", that ... of high oxygen presence, leading to enhanced lactate ... cells still choose glucose fermentation. A variety of ...
(Date:4/27/2015)... Diego, Calif. (PRWEB) April 27, 2015 ... of drug and chemical toxicity carries implications for advancing ... speaker April 28 at National University , the ... and presentation by Dr. Hanzlik, a professor at the ... drug metabolism and drug design, starts at 5 p.m. ...
(Date:4/27/2015)... BRUNSWICK, New Jersey , 27 ... société de découverte médicamenteuse spécialisée dans ... antibiotiques destinés à soigner les infections ... aujourd,hui la présentation de données prouvant ... majeur, le TXA709, dans la lutte ...
Breaking Biology Technology:Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6
... in a line of reports paints a bleak picture ... such financing could be at its lowest level in ... to year's end. , ,The Money Tree Survey ... and the National Venture Capital Association, indicates that, unless ...
... Chippewa Valley representatives hope to score points with medical ... the largest medical device tradeshow in the Midwest. ... Minneapolis Convention Center on November 2nd and 3rd is ... company executives. , ,The twelve representatives include economic development ...
... Madison, Wis. - Sonic Foundry Inc. announced today ... "E-rate" program, which offers schools around the country the ... , ,The E-rate program is designed to provide discounts ... for the cost of education technology. Funded technology includes ...
Cached Biology Technology:While some bemoan lack of venture capital, entrepreneur touts `bootstrapping' for cash 2While some bemoan lack of venture capital, entrepreneur touts `bootstrapping' for cash 3While some bemoan lack of venture capital, entrepreneur touts `bootstrapping' for cash 4Chippewa Valley reps hope to score at Twin Cities tradeshow 2
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... determined that milk thistle extract, a widely used ... on the course of patients with alcoholic liver ... These findings are published in The American ... studies, milk thistle extracts have been shown to ...
... more than half of children with sore throat, exceeding ... antibiotics for 27 percent of children who received an ... 9 issue of JAMA. , Pharyngitis (inflammation of the ... to family medicine physicians and pediatricians, according to background ...
... young scientists in the University of York's Department of ... patients some of the unpleasant and dangerous side-effects of ... together with post-doctoral research fellow Mark Godber, have developed ... tumours more efficiently. , Now, the group has secured ...
Cached Biology News:Children overprescribed antibiotics for sore throat 2Young scientists turn to gel to ease side-effects of cancer treatment 2
TUNEL Apoptosis Detection Kit...
... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Mouse Axl MAb (Clone 175128)...
Biology Products: